Innoviva Inc (INVA)

Dec 16, 2024, 7:00 AM EST - 4 weeks ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 1:15 AM EST - 4 weeks ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 2 months ago

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 6, 2024, 4:05 PM EST - 2 months ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Oct 15, 2024, 7:00 AM EDT - 3 months ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Sep 4, 2024, 7:00 AM EDT - 4 months ago

Innoviva to Participate in Upcoming Investor Conferences

Jul 31, 2024, 4:05 PM EDT - 6 months ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jun 18, 2024, 1:44 PM EDT - 7 months ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Jun 3, 2024, 7:00 AM EDT - 8 months ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 9 months ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 7:00 AM EDT - 9 months ago

Innoviva to Participate in the BofA Securities Health Care Conference

Apr 24, 2024, 7:00 AM EDT - 9 months ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Mar 4, 2024, 4:01 PM EST - 11 months ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Feb 29, 2024, 4:05 PM EST - 11 months ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 28, 2024, 2:48 PM EST - 11 months ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Nov 1, 2023, 4:15 PM EDT - 1 year ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 9, 2023, 1:48 PM EDT - 1 year ago

Innoviva: A Lot Of Moving Parts

Sep 19, 2023, 8:30 AM EDT - 1 year ago

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 18, 2023, 8:00 AM EDT - 1 year ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Aug 25, 2023, 4:52 PM EDT - 1 year ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 2, 2023, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Jul 11, 2023, 8:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Jun 6, 2023, 4:05 PM EDT - 1 year ago

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

May 23, 2023, 10:32 PM EDT - 1 year ago

FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 6:42 PM EDT - 1 year ago

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 11, 2023, 6:45 PM EDT - 1 year ago

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

May 9, 2023, 4:32 PM EDT - 1 year ago

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Apr 28, 2023, 5:30 PM EDT - 1 year ago

Innoviva Announces Retirement of Board Chairman

Apr 17, 2023, 4:31 PM EDT - 1 year ago

Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee

Apr 17, 2023, 9:00 AM EDT - 1 year ago

Innoviva Stock Trading Halted Today

Mar 13, 2023, 6:24 PM EDT - 2 years ago

Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic

Feb 28, 2023, 4:10 PM EST - 2 years ago

Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress

Jan 10, 2023, 4:05 PM EST - 2 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

ARMP

Nov 30, 2022, 4:30 PM EST - 2 years ago

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Nov 9, 2022, 4:05 PM EST - 2 years ago

Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Oct 19, 2022, 8:00 AM EDT - 2 years ago

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

Oct 14, 2022, 4:10 PM EDT - 2 years ago

La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022

Sep 8, 2022, 7:00 AM EDT - 2 years ago

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Aug 22, 2022, 8:55 AM EDT - 2 years ago

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Jul 27, 2022, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Jul 13, 2022, 5:41 PM EDT - 2 years ago

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

TBPH

Jul 13, 2022, 4:32 PM EDT - 2 years ago

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment

RPRX

Jul 11, 2022, 8:34 PM EDT - 2 years ago

LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of La Jolla Pharmaceutical Company - LJPC

Jul 11, 2022, 9:17 AM EDT - 2 years ago

Innoviva Completes Acquisition of Entasis Therapeutics